Less Support for Drug-Eluting Stents?

Are drug-eluting stents safe? That's what a recent FDA panel wanted to know amid the recent controversy concerning the medical device used to help battle arteriosclerosis.

The issue arose when a study by the Cleveland Clinic, published in December's American Journal of Medicine, showed an increased risk of late-stent thrombosis -- or formation of blood clots -- when using drug-eluting stents over the more conventional bare-metal stent.

Stents are used to help keep open arteries that have clogged over time. The FDA approved the first bare-metal stent, developed by Johnson & Johnson (NYSE: JNJ  ) , for use in 1994. The first drug-eluting stent, Cypher, also developed by Johnson & Johnson, was approved in 2003. Since then, the FDA has also approved Taxus, the drug-eluting stent sold by Boston Scientific (NYSE: BSX  ) , making it a two-horse race.

And the competition is slated to increase. Medtronic (NYSE: MDT  ) , which already sells its drug-eluted stent Endeavor in Europe, expects to receive FDA approval next year. Abbott (NYSE: ABT  ) also plans to come to market with its XIENCE V stent system, which was obtained as part of the Boston Scientific acquisition of Guidant.

The increasing competition comes as no surprise, given the potential revenues at stake. Boston Scientific, in its most recent quarterly filing, estimated that the coronary stent market for 2006 is roughly $6 billion worldwide, with 90% percent of the revenues generated from drug-eluting stents. With such a large percentage of revenues from the market, it is no wonder that stent makers would be concerned that the FDA might pull the plug on drug-eluted stents.

And we have already seen what the failure of a medical or pharmaceutical product can do to a company's future; just look at Pfizer's torcetrapib failure-to-launch or the withdrawal of Merck's Cox-2 Inhibitor Vioxx.

Fool's final word
The FDA concluded that under the recommended usages and the adherence to post-surgical prescriptions, drug-eluted stents have benefits that outweigh their risks. It was when the drug-coated stents were used off-label or not as intended that the risks were greater. Fellow Fool contributor Stephen Albainy-Jenei sees it as having little effect on the sales of drug-eluting stents.

I think the conclusions from the panel represent a good-faith-take on the newer stents, which is good news for drug companies. For instance, Boston Scientific, which generated 30% of its net sales from drug-eluted stents in this past third quarter, already had a 5% drop in U.S. sales of Taxus from third-quarter 2005 -- a move attributed to the recent negative studies.

Hey! Be Foolish and catch up on the stent saga:

Pfizer and Johnson & Johnson are both Motley Fool Income Investor recommendations. Find more dividend superstars with a free 30-day trial of James Early's low-risk, high-reward newsletter service.

Fool contributor Matthew Crews welcomes your feedback -- really! He has no financial position in any of the companies mentioned. The Motley Fool has an ironclad disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 536579, ~/Articles/ArticleHandler.aspx, 10/23/2014 6:07:56 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement